Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Histological confirmation of adenocarcinoma of the breast stage 0-III.
• Evidence of hormone sensitivity with estrogen receptor (ER) and/or progesterone receptor (PR) positive ≥ 1%) of primary tumor tissue.
• Premenopausal either by continuation of menstrual period or estradiol level ≥ 10 pg/ml.
• Will be starting on ovarian suppression in combination with aromatase inhibitor (letrozole, anastrozole, or exemestane).
• ECOG Performance Status (PS) ≤ 3.
• Ability to complete questionnaire(s) by themselves or with assistance.
• Provide written informed consent.
• Willing to return to enrolling institution for follow-up.

Exclusion Criteria

• Self-report of vaginal itching, dryness, or dyspareunia at baseline.
• Previous history of pelvic reconstruction surgery.
• Co-morbid systemic illnesses or oproper assessment of the treatment.
• Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy.
  • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.